Literature DB >> 9596300

Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients.

D R Nunley1, W Grgurich, A T Iacono, S Yousem, N P Ohori, R J Keenan, J H Dauber.   

Abstract

OBJECTIVE: To assess the incidence of pseudomonal infection, colonization, and inflammation in the allograft of lung transplant recipients with cystic fibrosis (CF) as compared with recipients with other end-stage lung disease.
DESIGN: Retrospective review.
SETTING: University medical center transplant service. PATIENTS: All patients with CF and chronic pseudomonal infection (n=62) and patients with nonseptic end-stage lung disease (n=52) receiving a double lung transplant between October 1983 and March 1996.
RESULTS: Fifty lung transplant recipients with CF survived beyond postoperative day (POD) 15 and were subject to sequential bronchoscopy with BAL. Forty-four CF lung transplant recipients had Pseudomonas isolated from the allograft by median POD 15 as compared with 21 non-CF lung transplant recipients (p<0.001) with isolation at median POD 158 (p<0.0001). Thirteen CF lung transplant recipients had histologic evidence of infection when Pseudomonas was isolated as compared with only three of the non-CF lung transplant recipients (p<0.01). These infections occurred earlier in the CF lung transplant recipients (median POD 10 vs 261) (p<0.01). When compared with non-CF lung transplant recipients, CF lung transplant recipients with Pseudomonas isolated but without concomitant histologic infection (colonized) were demonstrated to have increased number of polymorphonuclear cells (PMNs) in the BAL fluid recovered from the allograft (17.66+/-24.94 x 10(6) cells vs 3.46+/-4.73 x 10(6)) (p<0.05). Non-CF lung transplant recipients who became colonized with Pseudomonas also had a greater number of PMNs recovered when compared with non-CF lung transplant recipients who did not have Pseudomonas (22.32+/-34.00 x 10(6) cells vs 0.21+/-0.18 x 10(6)) (p<0.01). Nine of 32 (28%) lung transplant recipients with CF have died from pseudomonal allograft infections, but this is no greater than 4 of 21 (19%) deaths related to Pseudomonas infection in recipients without CF (p=0.34).
CONCLUSIONS: Isolation of Pseudomonas from the lung allograft occurs more frequently and earlier after transplantation in recipients with CF. While infections related to Pseudomonas also occur more frequently in recipients with CF, there is no increase in mortality. There is an intense inflammatory response in the lung allograft associated with the isolation of Pseudomonas in recipients with and without CF.

Entities:  

Mesh:

Year:  1998        PMID: 9596300     DOI: 10.1378/chest.113.5.1235

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

Review 1.  Inhaled antibiotics for lower airway infections.

Authors:  Bradley S Quon; Christopher H Goss; Bonnie W Ramsey
Journal:  Ann Am Thorac Soc       Date:  2014-03

Review 2.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

Review 3.  Prevention of chronic rejection after lung transplantation.

Authors:  Anke Van Herck; Stijn E Verleden; Bart M Vanaudenaerde; Geert M Verleden; Robin Vos
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

4.  Mortality associated with Acinetobacter baumannii infections experienced by lung transplant recipients.

Authors:  D R Nunley; G S Bauldoff; J E Mangino; A L Pope-Harman
Journal:  Lung       Date:  2010-07-06       Impact factor: 2.584

5.  Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation.

Authors:  Aric L Gregson; Xiaoyan Wang; S Sam Weigt; Vyacheslav Palchevskiy; Joseph P Lynch; David J Ross; Bernard M Kubak; Rajan Saggar; Michael C Fishbein; Abbas Ardehali; Gang Li; Robert Elashoff; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

Review 6.  Gene therapy for cystic fibrosis.

Authors:  Christian Mueller; Terence R Flotte
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

7.  Pulmonary nodules and masses in lung transplant recipients: clinical and CT findings.

Authors:  Olivier Morla; Renan Liberge; Pierre Paul Arrigoni; Eric Frampas
Journal:  Eur Radiol       Date:  2014-06-05       Impact factor: 5.315

Review 8.  Chronic rhinosinusitis and nasal polyposis in cystic fibrosis: update on diagnosis and treatment.

Authors:  Suzie Hyeona Kang; Paulo de Tarso Roth Dalcin; Otavio Bejzman Piltcher; Raphaella de Oliveira Migliavacca
Journal:  J Bras Pneumol       Date:  2015 Jan-Feb       Impact factor: 2.624

9.  Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium.

Authors:  Jose A G Ferreira; John C Penner; Richard B Moss; Janus A J Haagensen; Karl V Clemons; Alfred M Spormann; Hasan Nazik; Kevin Cohen; Niaz Banaei; Elisabete Carolino; David A Stevens
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

10.  Microbiological profiles of sputum and gastric juice aspirates in Cystic Fibrosis patients.

Authors:  H Al-Momani; A Perry; C J Stewart; R Jones; A Krishnan; A G Robertson; S Bourke; S Doe; S P Cummings; A Anderson; T Forrest; S M Griffin; M Brodlie; J Pearson; C Ward
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.